Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Dr. Reddy's Laboratories Limited clinical trials
Also known as DRL.
The registry lists 249 studies whose lead sponsor is Dr. Reddy's Laboratories Limited or one of 3 companies grouped under it. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 4, 2026.
Keep track of what changes. Save the Dr. Reddy's Laboratories Limited studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Dr. Reddy's Laboratories Limited.
- Dr. Reddy's Laboratories Limited224 studiesSame company
Something wrong?
- Aurigene Discovery Technologies Limited12 studies →Subsidiary
Something wrong?
- Promius Pharma, LLC10 studies →Subsidiary
Something wrong?
- Dr. Reddy's Laboratories (Thailand) Limited1 study →Regional office
Something wrong?
- Dr. Reddy's Laboratories SAS1 studySame company
Something wrong?
- Dr. Reddys Laboratories, SA1 studySame company
Something wrong?
Focus areas
Conditions Dr. Reddy's Laboratories Limited leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 249. Browse all 249 →
- A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male ParticipantsNot yet recruitingNCT07744828Phase 1
- AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)Not yet recruitingNCT07640737Phase 2
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)RecruitingNCT05865002Phase 1
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)RecruitingNCT05984147Phase 1
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced LymphomaRecruitingNCT06755450Phase 1
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNot yet recruitingNCT06193187Phase 1
Sponsor listed in the registry: Dr. Reddy's Laboratories (Thailand) Limited
- Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous RouteRecruitingNCT06126042Phase 1
- A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)TerminatedNCT06761586Phase 1
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- First in Human, Dose Escalation, Dose Expansion Study of AUR105TerminatedNCT05605119Phase 1
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal CancersTerminatedNCT06760702Phase 2
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and PharmacodynamicsTerminatedNCT05607199Phase 1
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced MalignanciesTerminatedNCT05861947Phase 1
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction AdenocarcinomaTerminatedNCT07040059Phase 1/2
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular LymphomaCompletedNCT03976102Phase 3
- A Phase III Transition Study of DRL Rituximab to Reference Medicinal ProductsCompletedNCT04268771Phase 3
- A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe PsoriasisCompletedNCT04207801Phase 2
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)CompletedNCT04855721Phase 2
Sponsor listed in the registry: Aurigene Discovery Technologies Limited
- A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type PsoriasisCompletedNCT02173301Phase 2
- A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)CompletedNCT03421197Phase 2
- Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 PatientsTerminatedNCT04529499Phase 3
- Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-Status unknownNCT05140655
Sponsor listed in the registry: Dr. Reddy's Laboratories SAS
- Dermal Safety Study to Evaluate Potential Irritation of Abametapir LotionCompletedNCT02061813Phase 1
- Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy VolunteersCompletedNCT01518699Phase 1
- Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) InfectionStatus unknownNCT04640233Phase 2/3
- Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice InfestationCompletedNCT02097485Phase 2
- A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne VulgarisCompletedNCT03290027Phase 3
- A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 WeeksCompletedNCT03292640Phase 3
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne VulgarisCompletedNCT03599193Phase 2
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release CapsulesCompletedNCT03340961Phase 2
- Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15CompletedNCT03554772Phase 2
- A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice InfestationCompletedNCT02060903Phase 3
- A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne VulgarisCompletedNCT03341910Phase 2
- Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice InfestationCompletedNCT02062060Phase 3
- A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice InfestationCompletedNCT02010333Phase 2
- Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir LotionCompletedNCT02062073Phase 1
- An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice InfestationCompletedNCT01336647Phase 2
- Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice InfestationCompletedNCT01907490Phase 2
- Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and ScalpCompletedNCT02654717Phase 2
Sponsor listed in the registry: Promius Pharma, LLC
- Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT02296775Phase 1/2
- Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal CancerStatus unknownNCT02301962Phase 4
- A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment PeriodCompletedNCT03116698Phase 2/3
- Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating MigraineCompletedNCT02571049Phase 2
- A Study to Assess the Efficacy, Safety and Tolerability of DFD-04CompletedNCT02828241Phase 2
- Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting ConditionsCompletedNCT03696329Phase 1
- Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting ConditionsCompletedNCT03706300Phase 1
- Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed ConditionsCompletedNCT03702855Phase 1
- DFN-11 Injection in Episodic Migraine With or Without AuraCompletedNCT02569853Phase 3
- Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine HeadachesCompletedNCT02472418Phase 2
- DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT02131324Phase 2
Sponsor listed in the registry: Promius Pharma, LLC
- A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque PsoriasisCompletedNCT02635204Phase 3
Sponsor listed in the registry: Promius Pharma, LLC